Janssen Ups Influenza Investment with US$780 M Bet on Cidara’s AVC Platform

By Michelle Liu

Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)

Published: 21 Apr-2021

DOI: 10.3833/pdr.v2021.i4.2608     ISSN: 1756-7874

Section: Research & Development



Janssen Pharmaceuticals has entered into a worldwide license and collaboration agreement with Cidara Therapeutics to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details